Detail akcie Xinhua Pharm online

Business Summary: SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Shandong Xinhua Pharmaceutical Co Ltd revenues increased 8% to RMB8.1B. Net income increased 21% to RMB496.5M. Revenues reflect Preparations segment increase of 14% to RMB3.64B, Pharmaceutical Intermediates and Others segment increase of 18% to RMB1.34B, China/Hong Kong segment increase of 21% to RMB5.93B. Net income benefited from Chemical Raw Medicine segment income increase of 41% to RMB684.6M.